Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam

Xianshi Zhou, Fanwei Wu
Xianshi Zhou
aEmergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
bGuangdong Provincial Key Laboratory of Research on Emergency in TCM, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanwei Wu
cFamous Doctor Hall, Bao’an TCM Hospital Group, Shenzhen, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01942-19
  • Article
  • Info & Metrics
  • PDF
Loading

LETTER

We read with great interest the article by Liu et al. (1) in an issue of Antimicrobial Agents and Chemotherapy. The article concluded that the clinical efficacy of 2 g cefoperazone-sulbactam every 12 h was noninferior to 2 g cefepime every 12 h for patients with hospital-acquired pneumonia/health care-associated pneumonia. Although the study sounds interesting, some important issues should be discussed.

First, Liu et al. should be commended for performing intent-to-treat (ITT) analysis and per-protocol analysis to reduce biases. However, their data set of ITT analysis was questionable. ITT analysis is a statistical method that compares the data between the study groups and control groups after the subjects have been randomly allocated, irrespective of protocol deviations, participant compliance, or withdrawal in each group (2, 3). In the article by Liu et al., after the original random allocation, there were 79 and 87 patients in the cefoperazone-sulbactam group and the cefepime group, respectively; thus, ITT analysis should include 79 and 87 patients in each arm rather than 71 and 83 shown in Table 1. What is more, Table 2 shows that data from only 55 and 64 patients in each group were included to analyze the treatment duration in different treatment arms; thus, we wonder why data were missing for some subjects.

Second, compared with the cefepime arm, the cefoperazone-sulbactam arm had a lower body mass index (BMI) after randomization (P < 0.05); then, we wonder whether the randomization was complete As BMI might affect the mortality of the patients with pneumonia and alter the blood concentration and efficacy of the antibiotics (4), we suggest the authors adjust the variable of BMI in their analysis to make their results more persuasive.

Third, the differences in the ratio of adverse events (AEs) in the two arms should not be ignored. According to Table 4, the death rate in the cefoperazone-sulbactam arm was twice more than in the cefepime arm (37.8% versus 18.2%). The proportion of serious adverse events (SAEs) was almost 3 times in the former arm than the later arm (15.2% versus 5.7%). Considering the many SAEs in the cefoperazone-sulbactam arm, we suggest the safety of cefoperazone-sulbactam should be checked and verified in future large sample studies.

Last, we appreciate Liu et al. for their innovative work, but further studies are needed before any rigorous conclusions can be made.

ACKNOWLEDGMENTS

The work of this submission was conducted at the Emergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

We declare that all the authors have participated in the conception or preparation of this manuscript.

FOOTNOTES

  • For author reply, see https://doi.org/10.1128/AAC.02028-19.

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Liu J-W,
    2. Chen Y-H,
    3. Lee W-S,
    4. Lin J-C,
    5. Huang C-T,
    6. Lin H-H,
    7. Liu Y-C,
    8. Chuang Y-C,
    9. Tang H-J,
    10. Chen Y-S,
    11. Ko W-C,
    12. Lu M-C,
    13. Wang F-D
    . 2019. Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia. Antimicrob Agents Chemother 63:e00023-19. doi:10.1128/AAC.00023-19.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Heritier SR,
    2. Gebski VJ,
    3. Keech AC
    . 2003. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 179:438–440. doi:10.5694/j.1326-5377.2003.tb05627.x.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Montori VM,
    2. Guyatt GH
    . 2001. Intention-to-treat principle. CMAJ 165:1339–1341.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Nie W,
    2. Zhang Y,
    3. Jee SH,
    4. Jung KJ,
    5. Li B,
    6. Xiu Q
    . 2014. Obesity survival paradox in pneumonia: a meta-analysis. BMC Med 12:61. doi:10.1186/1741-7015-12-61.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam
Xianshi Zhou, Fanwei Wu
Antimicrobial Agents and Chemotherapy Jan 2020, 64 (2) e01942-19; DOI: 10.1128/AAC.01942-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam
Xianshi Zhou, Fanwei Wu
Antimicrobial Agents and Chemotherapy Jan 2020, 64 (2) e01942-19; DOI: 10.1128/AAC.01942-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596